Trials / Available
AvailableNCT05974410
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- AVM Biotechnology Inc · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.
Conditions
- Glioblastoma
- Squamous Cell Carcinoma
- Hodgkin Lymphoma
- Non-hodgkin Lymphoma
- Breast Cancer
- Prostate Cancer
- Gastric Cancer
- Ovarian Cancer
- Acute Leukemia
- Pancreatic Cancer
- Spindle Cell Sarcoma
- Cancer
- Tumor, Solid
- Tumor, Brain
- Esophageal Andeocarcinoma
- Mixed Phenotype AML
- Desmoplastic Round Cell Sarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVM0703 | small molecule immunomodulatory drug |
| DRUG | Hydrocortisone | physiologic circadian glucocorticoid |
| DRUG | Proton pump inhibitor |
Timeline
- First posted
- 2023-08-03
- Last updated
- 2025-10-02
Source: ClinicalTrials.gov record NCT05974410. Inclusion in this directory is not an endorsement.